tradingkey.logo
tradingkey.logo
Search

Hoth Therapeutics Says 100% Of Patients Achieved Primary Endpoint In HT-001 Phase 2A Trial

ReutersJun 24, 2025 3:04 PM
facebooktwitterlinkedin

- Hoth Therapeutics Inc HOTH.O:

  • HOTH THERAPEUTICS HT-001 INTERIM RESULTS FIRST-IN-CLASS TOPICAL THERAPY PRESERVES CANCER TREATMENT WHILE RESOLVING DERMATOLOGIC SIDE EFFECTS

  • HOTH THERAPEUTICS INC - 100% OF PATIENTS ACHIEVED PRIMARY ENDPOINT IN PHASE 2A TRIAL

  • HOTH THERAPEUTICS INC - TOPICAL THERAPY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI